Role of the VEGF 936 gene polymorphism and VEGF-A levels in the late-term arteriovenous fistula thrombosis in patients undergoing hemodialysis

PurposeVascular access is vital for hemodialysis patients. A major factor that facilitates arteriovenous (AV) fistula failure is stenosis and thrombosis due to intimal hyperplasia developing in the venous segment of AV fistula. It has been reported that VEGF accelerated re-endothelialization, reduction in intimal thickening, and/or mural thrombus formed in the injured vascular structures. In this study, we aimed to identify the effect of the VEGF 936 gene polymorphism and vascular endothelial growth factor-A (VEGF-A) levels in the late period of AV fistula loss in hemodialysis patients.MethodsThe study was carried out with a patient group of 42 individuals who experienced two or more fistula thrombosis in the late period after the AV fistula operation and also a control group of 38 patients who have not had any AV fistula thrombosis history for 3 years or more. All participants were assessed for VEGF-936C/T gene polymorphism and VEGF-A levels.ResultsVEGF-936C/T genotypes were determined in the large proportion in the control group (31.6 %), while VEGF-936C/C genotypes were determined in a large proportion in the patient group (90.5 %). Individuals carrying the VEGF-936C/C genotype had an increased risk of 5.54 for getting AV fistula thrombosis. The VEGF-A levels of patient group (27.3 ± 43.5 pg/ml) were significantly lower than those of the control group (70.7 ± 53.1 pg/ml).ConclusionThere is an increased risk of AV fistula thrombosis in individuals carrying the VEGF-936C/C genotype. The other renal replacement modalities should be considered in patients with this genotype. As a result, it will be possible to prevent the morbidity and mortality due to fistula failure.

[1]  M. Abd el-Fattah,et al.  Evaluation of circulating vascular endothelial growth factor and soluble adhesion molecules as reliable predictors of native arteriovenous fistula thrombosis in chronic hemodialysis patients. , 2008, Clinical biochemistry.

[2]  N. Ferrara,et al.  Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis , 1999 .

[3]  W. G. Daniel,et al.  Elevated VEGF‐plasma levels in young patients with mild essential hypertension , 2009, European journal of clinical investigation.

[4]  D. Cha,et al.  Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients , 2009, Nephrology.

[5]  大谷 規彰.  Blockade of vascular endothelial growth factor suppresses experimental restenosis after intraluminal injury by inhibiting recruitment of monocyte lineage cells , 2005 .

[6]  D. Choudhury,et al.  Angiotensin converting enzyme inhibitors maintain polytetrafluroethylene graft patency. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  S. Rački,et al.  Vascular Access for Hemodialysis , 2021, Emergency Management of the Hi‐Tech Patient in Acute and Critical Care.

[8]  R. M. Pilkey,et al.  Thrombophilia and the risk for hemodialysis vascular access thrombosis. , 2005, Journal of the American Society of Nephrology : JASN.

[9]  A. Biuckians,et al.  From the Southern Association for Vascular Surgery The natural history of autologous fistulas as first-time dialysis access in the KDOQI era , 2008 .

[10]  Timmy Lee,et al.  Vascular stenosis: biology and interventions , 2007, Current opinion in nephrology and hypertension.

[11]  C. Zoccali,et al.  Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients , 2008, Journal of hypertension.

[12]  G. Yıldız,et al.  The Presence of PAI-1 4G/5G and ACE DD Genotypes Increases the Risk of Early-Stage AVF Thrombosis in Hemodialysis Patients , 2011, Renal failure.

[13]  L. Stitt,et al.  Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. , 2003, Journal of the American Society of Nephrology : JASN.

[14]  Seppo Ylä-Herttuala,et al.  Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. , 2007, Journal of the American College of Cardiology.

[15]  G. Gastl,et al.  Thrombocytes Are the Major Source for Soluble Vascular Endothelial Growth Factor in Peripheral Blood , 2000, Oncology.

[16]  J. Carrero,et al.  Associations of Vegf and Its Receptors Svegfr-1 and -2 with Cardiovascular Disease and Survival in Prevalent Haemodialysis Patients Introduction , 2022 .

[17]  James F Glockner,et al.  Increased shear stress with upregulation of VEGF-A and its receptors and MMP-2, MMP-9, and TIMP-1 in venous stenosis of hemodialysis grafts. , 2008, American journal of physiology. Heart and circulatory physiology.

[18]  W. Renner,et al.  A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels , 2000, Journal of Vascular Research.

[19]  M. Allon,et al.  Impact of obesity on arteriovenous fistula outcomes in dialysis patients. , 2007, Kidney international.

[20]  A. Narayana,et al.  Hemodialysis vascular access dysfunction from basic biology to clinical intervention. , 2002, Advances in renal replacement therapy.

[21]  Ikuo Inoue,et al.  A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. , 2002, Diabetes.

[22]  J. Isner,et al.  Somatic gene therapy in the cardiovascular system. , 2001, Annual review of physiology.

[23]  F. Port,et al.  Haemodialysis vascular access problems in Canada: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS II). , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  G. Knoll,et al.  The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene. , 2006, Blood.

[25]  M. Clauss.  Molecular Biology of the VEGF and the VEGF Receptor Family , 2000, Seminars in thrombosis and hemostasis.

[26]  Young Soo Kim,et al.  Ultrasonographic measurement of intima-media thickness of radial artery in pre-dialysis uraemic patients: comparison with histological examination. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  S. Ylä-Herttuala,et al.  Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[28]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[29]  G. Hospers,et al.  Platelets and Granulocytes, in Particular the Neutrophils, Form Important Compartments for Circulating Vascular Endothelial Growth Factor , 2004, Angiogenesis.

[30]  J. Gilabert-Estellés,et al.  Vascular endothelial growth factor polymorphisms (-460C/T, +405G/C, and 936C/T) and endometriosis: their influence on vascular endothelial growth factor expression. , 2009, Fertility and sterility.

[31]  P. Ravani,et al.  Clinical epidemiology of arteriovenous fistula in 2007. , 2007, Journal of nephrology.

[32]  S. Ylä-Herttuala,et al.  Biology of vascular endothelial growth factors , 2006, FEBS letters.

[33]  I. Brandslund,et al.  The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. , 2010, Gynecologic oncology.

[34]  D. Windus.  Permanent vascular access: a nephrologist's view. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  J. Moon,et al.  Arteriovenous Fistula Patency Associated with Angiotensin-Converting Enzyme I/D Polymorphism and ACE Inhibition or AT1 Receptor Blockade , 2009, Nephron Clinical Practice.

[36]  G. Lip,et al.  Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). , 2003, The American journal of cardiology.

[37]  M J Brescia,et al.  Chronic hemodialysis using venipuncture and a surgically created arteriovenous fistula. , 1966, The New England journal of medicine.

[38]  R. Friedl,et al.  Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. , 2002, Kidney international.

[39]  P. Blankestijn,et al.  Hemodialysis access graft failure: time to revisit an unmet clinical need? , 2005, Journal of nephrology.

[40]  Alberto Smith,et al.  Adenovirus-Mediated VEGF Gene Therapy Enhances Venous Thrombus Recanalization and Resolution , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[41]  Alberto Smith,et al.  Vascular endothelial growth factor naked DNA gene transfer enhances thrombus recanalization and resolution. , 2005, Journal of vascular surgery.

[42]  D. Mukhopadhyay,et al.  The rat femoral arteriovenous fistula model: increased expression of matrix metalloproteinase-2 and -9 at the venous stenosis. , 2008, Journal of Vascular and Interventional Radiology.